Silo Pharma (NASDAQ:SILO – Get Free Report) and Oculis (NASDAQ:OCS – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.
Institutional and Insider Ownership
5.6% of Silo Pharma shares are owned by institutional investors. Comparatively, 22.3% of Oculis shares are owned by institutional investors. 3.6% of Silo Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares Silo Pharma and Oculis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Silo Pharma | -6,726.39% | -81.75% | -66.35% |
| Oculis | -6,777.18% | -42.61% | -35.23% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Silo Pharma | 1 | 0 | 0 | 0 | 1.00 |
| Oculis | 1 | 0 | 9 | 0 | 2.80 |
Oculis has a consensus target price of $39.44, indicating a potential upside of 319.18%. Given Oculis’ stronger consensus rating and higher probable upside, analysts clearly believe Oculis is more favorable than Silo Pharma.
Risk & Volatility
Silo Pharma has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, Oculis has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500.
Valuation and Earnings
This table compares Silo Pharma and Oculis”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Silo Pharma | $70,000.00 | 39.75 | -$4.23 million | ($4.36) | -0.40 |
| Oculis | N/A | N/A | -$119.44 million | ($1.74) | -5.41 |
Silo Pharma has higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Silo Pharma, indicating that it is currently the more affordable of the two stocks.
Summary
Oculis beats Silo Pharma on 7 of the 13 factors compared between the two stocks.
About Silo Pharma
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company’s two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company’s research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
About Oculis
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.
Receive News & Ratings for Silo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
